Insights

Gathering insights about Ascenta…

Similar companies to Ascenta

Ascenta Tech Stack

Ascenta uses 8 technology products and services including WordPress, RSS, Google Fonts API, and more. Explore Ascenta's tech stack below.

WordPress
Content Management System
RSS
Content Management System
Google Fonts API
Font Scripts
jQuery
Javascript Libraries
WPBakery
Page Builders
Elementor
Page Builders
HTTP/3
Web & Portal Technology
Apache HTTP Server
Web Servers

Media & News

ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%
ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development, and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has presented the first dataset from the global registrational Phase III study (POLARIS-1) of the company's novel, investigational drug, Olverembatinib (HQP1351), in combination with low-intensity chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), in a poster presentation at the 67th American Society of Hematology (ASH) Annual Meeting, being held in Orlando, Florida.
Dec 08, 2025 | www.globenewswire.com
ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP
ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it presented four year follow-up data from its randomized controlled, registrational Phase II study of Olverembatinib in patients with tyrosine kinase inhibitor (TKI)-resistant/intolerant chronic-phase chronic myeloid leukemia (CML-CP), in a poster presentation at the 67th American Society of Hematology (ASH) Annual Meeting, being held in Orlando, Florida. Building on results released in an oral presentation at ASH 2023, these data reaffirm Olverembatinib's differentiated long-term efficacy and safety.
Dec 08, 2025 | www.globenewswire.com
ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment
ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development, and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has presented the latest data on Olverembatinib, the Company's novel drug, in second-line treatment of patients with chronic myeloid leukemia (CML) in chronic-phase (-CP), in a poster presentation at the 67th American Society of Hematology (ASH) Annual Meeting, being held in Orlando, Florida. This presentation provided an update on the results released in an oral presentation at ASH 2024 and featured data from a longer follow-up on efficacy and safety.
Dec 08, 2025 | www.globenewswire.com
ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances
ROCKVILLE, Md. and SUZHOU, China, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development, and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it presented the latest results from a Phase Ib/II study of Lisaftoclax (APG-2575), a key investigational drug candidate in the Company's pipeline, in combination with azacitidine (AZA) in patients with newly diagnosed or prior venetoclax–exposed myeloid malignancies in a poster presentation at the 67th American Society of Hematology (ASH) Annual Meeting, being held in Orlando, Florida.
Dec 07, 2025 | www.globenewswire.com
Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting
ROCKVILLE, Md. and SUZHOU, China, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization novel, differentiated therapies to address unmet medical needs in cancer, announced that it has presented an oral report featuring the latest results from a registrational Phase II study conducted in China of Lisaftoclax (APG-2575), a key drug candidate in the Company‘s pipeline, as a monotherapy in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis), at the 67th American Society of Hematology (ASH) Annual Meeting, being held in Orlando, FL. Data from this pivotal trial supported the NDA approval that was granted to Lisaftoclax by China's National Medical Products Administration (NMPA) in July 2025.
Dec 06, 2025 | www.globenewswire.com
Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA
ROCKVILLE, Md. and SUZHOU, China, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance from the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct a global registrational Phase III study (POLARIS-1; NCT06051409 ) of its compound under investigation, olverembatinib, in combination with chemotherapy for the treatment of newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). As the second global registrational Phase III study of olverembatinib that has been cleared by regulators in the US and Europe, the POLARIS-1 study is simultaneously enrolling patients across trial centers in multiple countries in order to accelerate olverembatinib's path to registration worldwide, particularly in the US and European markets.
Dec 04, 2025 | www.globenewswire.com
Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature's Signal Transduction and Targeted Therapy
Largest prospective clinical trial to-date in a rare subtype of GIST ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced the publication of clinical and translational data from a Phase Ib study (NCT03594422) on the Company's novel drug, olverembatinib (HQP1351), in patients with gastrointestinal stromal tumors (GIST), by the renowned scientific journal Signal Transduction and Targeted Therapy (Impact Factor: 52.7).
Nov 24, 2025 | www.globenewswire.com

Ascenta's Email Address Formats

Ascenta uses at least 1 format(s):

Ascenta Email Formats	Example	Percentage
First@ascentagroup.com	John@ascentagroup.com	50%
First@ascentagroup.com	John@ascentagroup.com	50%

Frequently Asked Questions

What is Ascenta's stock symbol?

Ascenta is a publicly traded company; the company's stock symbol is AAPG.

What is Ascenta's official website and social media links?

Ascenta's official website is ascentagroup.com and has social profiles on LinkedIn.

What is Ascenta's SIC code NAICS code?

Ascenta's SIC code is 8742 - Management Consulting Services NAICS code is 541613 - Marketing Consulting Services.

How many employees does Ascenta have currently?

As of December 2025, Ascenta has approximately 51 employees across 2 continents, including North AmericaAsia. Key team members include Chief Operating Officer: S. F.Assistant Owner: M. R.Director Of Operations: B. E.. Explore Ascenta's employee directory with LeadIQ.

What industry does Ascenta belong to?

Ascenta operates in the Advertising Services industry.

What technology does Ascenta use?

Ascenta's tech stack includes WordPressRSSGoogle Fonts APIjQueryWPBakeryElementorHTTP/3Apache HTTP Server.

What is Ascenta's email format?

Ascenta's email format typically follows the pattern of First@ascentagroup.com. Find more Ascenta email formats with LeadIQ.

Ascenta

Q: What is Ascenta's official website and social media links?

Ascenta's official website is ascentagroup.com. Ascenta has social profiles on LinkedIn.

Q: How many employees does Ascenta have currently?

Ascenta has approximately 51 employees.

Q: What technology does Ascenta use?

Ascenta's tech stack includes Apache HTTP Server, WordPress, X-Content-Type-Options, jQuery, Yoast SEO.

Advertising ServicesNew York, United States51-200 Employees

Ascenta is a sales and marketing partner that provides face-to-face customer and donor acquisition services to leading commercial and non-profit organizations. We’re experts at leveraging the power of human connection to build lasting customer relationships.

Company Overview

Website: ascentagroup.com
SIC Code: 8742 - Management Consulting Services
Stock Symbol: AAPG
NAICS Code: 541613 - Marketing Consulting Services
Employees: 51-200

Media & News

Funding & Financials

$10M$25M
Ascenta's revenue is estimated to be in the range of $10M$25M

Funding & Financials

$10M$25M
Ascenta's revenue is estimated to be in the range of $10M$25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Ascenta

Mavrck

NeoReach

Open Influence

Sideqik

Tidal Labs

Traackr

Klear - Influencer Marketing Platform

Upfluence

Ascenta Tech Stack

Media & News

ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%

ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP

ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment

ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances

Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting

Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA

Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature's Signal Transduction and Targeted Therapy

Ascenta's Email Address Formats

Frequently Asked Questions

What is Ascenta's stock symbol?

What is Ascenta's official website and social media links?

What is Ascenta's SIC code NAICS code?

How many employees does Ascenta have currently?

What industry does Ascenta belong to?

What technology does Ascenta use?

What is Ascenta's email format?

Ascenta

Company Overview

Media & News

ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%

ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP

ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?